Symani Surgical System

MMI's Symani Surgical System is a microsurgery robot with the world's smallest wristed microinstruments, providing tremor filtration and motion scaling to let surgeons reconnect blood vessels and lymphatic ducts as small as ~0.1 mm in reconstructive, lymphatic, and soft-tissue procedures.

Symani Surgical System is at the research stage: it exists, but DEPLOY has no verified real-world deployment on record. Manufacturer capability claims should be read as claims pending independent verification.

Symani Surgical System is made by Medical Microinstruments (MMI), based in Pisa, Italy.

Symani Surgical System is at research stage and is not yet available for sale.

Symani Surgical System has 1 regulatory record on the DEPLOY registry: FDA 510(k) clearance, cleared. See the Regulatory filings section for each agency source.

On the DEPLOY registry, comparable surgical robots to Symani Surgical System include da Vinci (and Ion), Edge Multi-Port Surgical Robot, Edison Histotripsy System, Stryker Mako SmartRobotics.

Symani Surgical System and da Vinci (and Ion) (Intuitive Surgical · 15 deployments) are both surgical robots on the DEPLOY registry. Symani Surgical System has 0 verified deployments on record. Compare both records for specs, safety, deployments, and verified-vs-claimed autonomy.

On DEPLOY's intelligence score, which blends verified deployments, safety, adoption, media, and IP signals, Symani Surgical System ranks in roughly the top 97% of surgical models tracked by the registry.

Symani Surgical System is at the research stage on the DEPLOY maturity ladder (research, prototype, pilot, commercial, production). Research stage means active development without commercial deployments on file.

No verified deployments of Symani Surgical System are currently on the DEPLOY registry. DEPLOY records deployments only when verified at a named site with a primary source; absence may reflect pre-deployment, research, or manufacturer-internal use.

Symani Surgical System has no incidents on record in the DEPLOY registry. This does not constitute a safety guarantee; it reflects the incidents DEPLOY has tracked and verified to date.

Yes. MMI (Medical Microinstruments) received FDA authorization to commercialize the Symani Surgical System in the US in April 2024. MMI also received IDE approval for the first robotic microsurgical study in Alzheimer's patients. Total funding is $220M including a $110M Series C.